Revel Pharmaceuticals unveils enzyme that cuts age‑related tissue compounds
Scientists at Revel Pharmaceuticals, led by Aaron Cravens, engineered an enzyme called CMLase that degrades advanced glycation end‑products (AGEs), chemical compounds that accumulate in human tissues with age and contribute to chronic diseases. The team used artificial‑intelligence screening of more than 50,000 microbial DNA sequences and directed‑evolution techniques to optimise the enzyme's activity.
In laboratory tests the enzyme reduced AGE levels in skin samples from a 70‑year‑old donor to levels comparable to those of a 30‑year‑old. The findings were published on 16 July in the journal Nature Communications, suggesting a new approach to mitigating tissue‑level ageing and its associated health risks.
Entities: Aaron Cravens · Advanced Glycation End‑products (AGEs) · CMLase · CMLase enzyme · Nature Communications · Revel Pharmaceuticals · advanced glycation end‑products
Claims
What the coverage asserts, and how well corroborated each claim is across sources.
- [○ 1 SOURCE] The enzyme CMLase was developed using AI analysis of over 50,000 microbial DNA sequences and directed‑evolution optimisation. (Research team at Revel Pharmaceuticals)
- [○ 1 SOURCE] In tests, skin from a 70‑year‑old donor treated with CMLase showed AGE levels comparable to those of a 30‑year‑old. (Aaron Cravens, Revel Pharmaceuticals)
- [● 2 SOURCES] The study describing CMLase was published on 16 July in the journal Nature Communications. (Study authors)
- [● 2 SOURCES] A laboratory‑designed enzyme called CMLase eliminates advanced glycation end‑products (AGEs) in human tissue samples. (Aaron Cravens, Revel Pharmaceuticals)
- [○ 1 SOURCE] Aaron Cravens is a founder and CEO of Revel Pharmaceuticals and the lead author of the enzyme study. (Study authors)